Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that by December 29, 2022, 65 patients have completed the pivotal Phase 3 clinical SPARKLE study with the lead candidate drug Orviglance.
On December 6, 2022, Ascelia Pharma announced that 58 patients had completed the SPARKLE study, which will include 80 patients in total. Since this announcement, 7 more patients have completed the study. The company expects to complete patient enrollment by February/March 2023 with topline results by mid-2023.
The SPARKLE study is the third and last of three clinical studies that form the Phase 3 program for Orviglance, the company’s orphan liver imaging agent.